Court forces settlement in FROVA patent case

A federal district court forces a settlement in the patent case between Mylan (MYL) and Endo Pharmaceuticals (ENDP) over the migraine drug FROVA (Frovatriptan Succinate Tablets). The court vacates its January 28, 2014 decision in favor of Endo paving the way for Mylan to launch its generic version after FDA approval instead of having to wait until November 7, 2015 when the 864 patent expires.

According to IMS Health, Frovatriptan sales in the U.S. last year were ~$66M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs